| || Regional Director Global Divestments, Sandoz, Holzkirchen (Munich) Germany
Would you like to work for a Global Generics and Biosimilars company and contribute to our mission to extend and improve people’s lives?
Responsibilities include: Leading tasks in all phases of divestment deals including origination and execution, from target identification, idea generation, prospect documents preparation, deal structuring through to deal closing. Overseeing due diligence work-streams with internal and external stakeholders.
• Taking a lead role in divestment activities, including buyer prospect, proposal development and deal closing
• Managing and delivering significant business results that reflect strategic thinking, creativity and individual initiative
• Identifying and addressing divestment needs by building, maintaining, and utilizing networks of relationships both internally and externally
• Selecting buyers at each stage of deal process and conducting valuation analysis of deals offers via financial modeling
• Scoping and developing high-yield work streams for each complex deal by defining the scope, breaking down work in meaningful structures and prioritizing the sequence of tasks
• Manage alliance with buyers and ensure compliance to executed contract
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz Biopharmaceuticals, a global business unit of Sandoz, comprises biosimilars, contract manufacturing and Glatopa 20mg (glatiramer acetate). It is a USD one billion business (2016 annual sales). As the pioneer and global leader in biosimilars, with sales in 86 countries and five marketed biosimilars in Europe, Sandoz is committed to increasing patient access to high-quality, life-enhancing biosimilars. Its biosimilar products (Omnitrope, Binocrit, Zarzio/Zarzio, Rixathon and Erelzi) have generated more than 340 million patient days of experience. Sandoz has a leading biosimilar pipeline and plans to launch a total of five biosimilars of major oncology and immunology biologics across major markets between 2017 and 2020. A division of the Novartis Group, Sandoz is well-positioned to continue leading the biosimilars industry based on its experience and capabilities in development, manufacturing, and commercialization.
Benefits of Working for Sandoz
• Competitive salary
• Performance based annual bonus
• Work/life integration
• Eligible to Sandoz pension plan
• 30 working days' holiday per calendar year
• Additional benefits
‘I came for the job, I stay for the culture’
| || The ideal candidate will have
• Bachelor degree, scientific or finance domain (preferred)
• Fluency in English is prerequisite, while knowledge of other languages would be an advantage
• Significant number of years relevant experience
• Understanding various facets of mergers, integrations, spin-offs and/or divestiture transactions, including options analyses and recommendations
• Leading teams with strategic planning and business reviews; growth, international expansion; and market opportunity sizing
• Strong track record of taking ownership and delivering results in a timely manner
• Preferred to have understanding of pharmaceutical business
We focus on creating an inclusive organisation and welcome people who have different knowledge, perspectives, experience and working styles from across the global population.